Peter David Suzdak
Director/Board Member at Acidophil LLC
Profile
Peter David Suzdak founded Cardioxyl Pharmaceuticals LLC in 2006, where he worked as President & Chief Executive Officer.
Dr. Suzdak also founded Artesian Therapeutics, Inc., where he worked as President & Chief Executive Officer.
Dr. Suzdak also currently works at Acidophil LLC, as Director.
Dr. Suzdak also formerly worked at Rexahn Pharmaceuticals, Inc., as Chief Executive Officer & Director from 2013 to 2018, Incara Pharmaceuticals Corp., as Director, Novo Nordisk A, as Director-Neurobiology Research in 1995, Aeolus Pharmaceuticals, Inc., as Independent Director from 2011 to 2013, Guilford Pharmaceuticals, Inc., as Senior Vice President-Research & Development in 2002, National Institute of Mental Health, as Associate-Pharmacology Research in 1988, and Corridor Pharmaceuticals, Inc., as Chief Scientific Officer.
Dr. Suzdak received his undergraduate degree from St. John's University and doctorate degree from the University of Connecticut.
Peter David Suzdak active positions
Companies | Position | Start |
---|---|---|
Acidophil LLC
Acidophil LLC Medical/Nursing ServicesHealth Services Acidophil LLC develops biotechnologies and products in the field of applied genetics and molecular engineering. It uses synthetic biology and/or synthetic chemistry to apply the lessons of evolution to the discovery and development of novel bioactive compounds and related production processes for a variety of market sectors. The company was founded by Sydney Brenner and Philip Goelet and is headquartered in Lutherville, MD. | Director/Board Member | - |
Former positions of Peter David Suzdak
Companies | Position | End |
---|---|---|
REXAHN PHARMACEUTICALS, INC. | Chief Executive Officer | 2018-11-13 |
AEOLUS PHARMACEUTICALS, INC. | Director/Board Member | 2013-05-07 |
Incara Pharmaceuticals Corp. | Director/Board Member | 2004-08-08 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Chief Tech/Sci/R&D Officer | 2001-12-31 |
NOVO NORDISK A/S | Chief Tech/Sci/R&D Officer | 1994-12-31 |
Training of Peter David Suzdak
St. John's University | Undergraduate Degree |
University of Connecticut | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
NOVO NORDISK A/S | Health Technology |
AEOLUS PHARMACEUTICALS, INC. | Health Technology |
Private companies | 8 |
---|---|
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
Incara Pharmaceuticals Corp. | Health Technology |
Artesian Therapeutics, Inc.
Artesian Therapeutics, Inc. BiotechnologyHealth Technology Artesian Therapeutics, Inc. develops and manufactures biopharmaceutical therapeutic products. Its products are used for the treatment of cardiovascular and other life threat diseases. The company was founded by Peter D. Suzdak in March 2002 and is located in Gaithersburg, MD | Health Technology |
Cardioxyl Pharmaceuticals LLC
Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | Health Technology |
Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD. | Health Technology |
National Institute of Mental Health | Government |
Acidophil LLC
Acidophil LLC Medical/Nursing ServicesHealth Services Acidophil LLC develops biotechnologies and products in the field of applied genetics and molecular engineering. It uses synthetic biology and/or synthetic chemistry to apply the lessons of evolution to the discovery and development of novel bioactive compounds and related production processes for a variety of market sectors. The company was founded by Sydney Brenner and Philip Goelet and is headquartered in Lutherville, MD. | Health Services |
Corridor Pharmaceuticals, Inc.
Corridor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Corridor Pharmaceuticals, Inc. develops and manufactures biopharmaceutical products. The company was founded on February 1, 2008 and is headquartered in Lutherville, MD | Health Technology |
- Stock Market
- Insiders
- Peter David Suzdak